Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116209 | 0.85 | MAPT (0.39) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL18066924 | 0.82 | GBA1 (0.32) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10103787 | 0.82 | SMN1; SMN2 (0.32) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL14584998 | 0.82 | MAPK1 (0.41) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12705 | 0.78 | — | — | |
| SCHEMBL15492423 | 0.78 | MAPT (0.56) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL22540946 | 0.77 | MAPT (0.33) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10263561 | 0.74 | HSD17B10 (0.36) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15490001 | 0.73 | HSD11B1 (0.33) | MAPTHSD17B10CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10264412 | 0.73 | MAPT (0.54) | MAPTSMN1; SMN2TSHRKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194932-A1 | IMPROVED INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | STEMSYNERGY THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
| EP-2410858-B1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194932-A1 | IMPROVED INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | MAPT 3977/4885HSD17B10 2096/4885CYP2C9 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.